A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Summary

TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).

Timeline

Start

2024-06-27

Primary completion

2025-06

Completion

2026-12

Drugs

Indications